Clinical trials: Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- CheckMate 650 (NCT02985957)
- Testing
- Nivolumab, Ipilimumab, Cabazitaxel
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 351 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT03674814
- Testing
- Enzalutamide, Relacorilant
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Chicago
Prostate Cancer Metastatic Castration Resistant
Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)
Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant.
- Trial name
- CURTAXEL (NCT02095717)
- Testing
- Curcumin, Taxotere
- Where
- 4 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Jean Perrin
Castrate-resistant Prostate Cancer
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
There will be two parts to this clinical research study. The purpose of each part is: Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with a standard dose of abiraterone acetate and prednisone…
- Trial name
- NCT01717898
- Testing
- BEZ235, Prednisone, Abiraterone acetate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Charles Ryan
Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic Solid Tumor
- Trial name
- NCT07423117
- Testing
- ITC-6146RO
- Volunteers
- 102 people
- Sponsor
- IntoCell, Inc
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
- Trial name
- NCT05519449
- Testing
- JANX007, Darolutamide
- Where
- 36 sites in United States, Australia
- Volunteers
- 272 people
- Sponsor
- Janux Therapeutics
Prostate Cancer
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated machine vision based image analysis of…
- Trial name
- NCT00578409
- Where
- United States
- Volunteers
- 758 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer
Memantine Hydrochloride in Prostate Cancer Patients
The goal of this clinical trial is to learn if long-term use of memantine hydrochloride can treat, prevent, or correct castration resistance and drug resistance in advanced prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
- Trial name
- NCT07164794
- Testing
- Memantine Hydrochloride
- Volunteers
- 15 people
- Sponsor
- Bin Xu
Prostate Cancer
Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer
The main objectives of this trial are: 1. To assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic CRPC who have not received prior chemotherapy. 2.
- Trial name
- NCT01748500
- Testing
- Pantoprazole
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University Health Network, Toronto
Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma
- Trial name
- NCT01338831
- Testing
- LFA102
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Hormone-resistant Prostate Cancer
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This is a research study for advanced prostate cancer. An experimental drug called AN-152 (also known as AEZS-108) will be used.
- Conditions
- Prostate Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01240629
- Testing
- laboratory biomarker analysis, questionnaire administration, doxorubicin-GnRH agonist conjugate AEZS-108
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Southern California
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
This phase II trial studies how well pembrolizumab works in treating patients with prostate cancer that has spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very…
- Conditions
- Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT02312557
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03218826
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- AtezoCab (NCT05168618)
- Testing
- Atezolizumab, Cabozantinib S-malate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Utah
Prostate Cancer
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
This clinical trial is being conducted to recommend a safe and tolerable phase 2 dose of docetaxel or cabazitaxel when combined with clarithromycin in men who have developed castrate-resistant prostate cancer.
- Trial name
- NCT03043989
- Testing
- Docetaxel, Cabazitaxel, Clarithromycin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone Refractory Prostate Cancer
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.
- Trial name
- HRPC (NCT00525408)
- Testing
- Mycobacterium w., Docetaxel
- Where
- 14 sites in India
- Volunteers
- 134 people
- Sponsor
- Cadila Pharnmaceuticals
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT03732820
- Testing
- olaparib, abiraterone acetate
- Where
- 132 sites in United States, Australia and 15 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Prostate Cancer Metastatic
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with…
- Trial name
- PERSEUS (NCT01360840)
- Testing
- EMD 525797, Standard of Care (SoC)
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 180 people
- Sponsor
- EMD Serono